Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Vitrolife

Vitrolife

Read in Swedish

Vitrolife AB (publ): Conference call interim report

09:00 / 18 October 2022 Vitrolife Press release

Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report January - September 2022. The presentation will be held in English.

Time: Thursday 27 October, 2022 at 10.00 a.m. CET.
Registration can preferably be done 10-15 minutes before the conference start time on:
Sweden dial in number: +46 (0) 8 5051 0086
International dial in number: +44 (0) 33 0551 0211
Conference name: Vitrolife AB, Interim Report Q3, 2022
Conference PIN: 4626923#
Vitrolife participants:
Thomas Axelsson, CEO
Patrik Tolf, CFO
The press release for the interim report will be released at 8.00 CET on the same day.
Before the conference call, presentation material will be available at the company web page, https://www.vitrolife.com/investors/Presentations/
A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 4626923#.
Gothenburg, 18 October 2022
VITROLIFE AB (publ)

_____________________________________________________________________________________________________________________________________________________________

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,150 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com.Website: www.vitrolife.com.

Show as PDF

Show original from Cision

Cision

This information was distributed by Cision http://www.cisionwire.se/